The susceptibilities of multiply resistant clinical isolates of Pseudomonas aeurginosa to ciprofloxacin, norfloxacin, and several beta-lactam and aminoglycoside antibiotics were evaluated. Ciprofloxacin also was compared with methicilin and vancomycin against methicillin-resistant Staphylococcus epidermidis and group JK corynebacteria. Ciprofloxacin exhibited the lowest MICs and MBCs for 90% of the isolates among all of the antibiotics tested against P. aeruginosa. In addition, ciprofloxacin exhibited excellent bactericidal activity against the gram-positive organisms. Clinical trials are necessary to confirm the in vitro results and monitor for emergence of resistance. Vancomycin is the drug of choice for infections caused by both methicillin-resistant S. epidermidis and JK diphtheroids. However, we have observed several patients who have developed severe toxicity with the use of this antibiotic, including the "Redman's syndrome," true drug-allergic skin rashes, liver abnormalities, and neutropenia (7, 15 Tobramycin 0.25-16 2 16 tration between 105 and 106 CFU/ml. Tubes containing 0.5 ml of serially diluted antibiotic were inoculated with 0.5 ml of diluted organism and incubated at 35°C for 20 h. All tubes were vortexed and reincubated for an additional 4 h before subculture for the MBC was performed. A similar procedure was followed for group JK corynebacteria, except that the test medium employed was tryptic soy broth supplemented with 0.1% Tween (14) . Ciprofloxacin exhibited at least four times greater activity against P. aeruginosa than any of the other antimicrobial agents tested ( Table 1 ). All of these organisms were multiply resistant to broad-spectrum beta-lactam antibiotics or aminoglycosides or both. Moreover, ciprofloxacin exhibited bactericidal activity against all of the strains tested, as evidenced by MBCs for 90% of the strains (MBC90s) which consistently were within 1 dilution of the MICs for 90% of the strains (MIC90s) (data not shown).
In addition, ciprofloxacin demonstrated excellent bactericidal activity against methicillin-resistant strains of S. epidermidis ( Table 2 ). The MIC90s for both methicillinsusceptible and -resistant organisms were 1 ,ugIml. Group JK corynebacteria were also uniformly susceptible to ciprofloxacin, which had an MIC90 of 1 ,ug/ml. Bactericidal activity was demonstrated in 9 of the 10 isolates tested (MBC90, 2 ,uglml) .
Ciprofloxacin is a new carboxylic acid quinolone antibiotic with good activity against gram-negative aerobic bacilli including most P. aeruginosa isolates (2, 3, 5, 6, 12) . However, little has been published assessing the in vitro susceptibilities of multiply resistant strains of P. aeruginosa to this quinolone. In one recent study evaluating 10 multiply resistant P. aeruginosa strains, ciprofloxacin exhibited MICs of 0.07 to 0.7 pg/ml (4) . Inhibitory activity of (n = 10) ciprofloxacin against 17 isolates of group JK corynebacteria was reported by Machka and Balg, but bactericidal activity was not evaluated (10) . Finally, there has been only one report of the activity of ciprofloxacin against methicillinresistant strains of S. epidermidis described recently (13).
In conclusion, our in vitro susceptibility data suggests that ciprofloxacin may be an effective bactericidal agent for the treatment of multiply resistant P. aeruginosa infections and may be an alternative to vancomycin in select patients with disease due to S. epidermidis and JK diphtheroids. We await clinical trials to confirm these in vitro results and monitor the potential emergence of quinolone-resistant isolates.
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